US-based AI startup RISA Labs ne Series A funding round mein $11.1 million (INR 100 crore se zyada) raise kiye hain, jisme Cencora Ventures aur Optum Ventures ne co-lead kiya hai. Yeh capital U.S. cancer clinics aur health systems mein RISA ke artificial intelligence-powered system ko launch karne ki speed badhayega jo oncology workflows ko streamline karta hai. Company ka flagship AI console, BOSS, complex oncology processes ko manageable tasks mein simplify karta hai jise AI agents execute karte hain. Yeh system cancer care ke liye design kiya gaya hai, jo complex payer rules, multi-drug regimens, aur disease-specific requirements ko handle kar sakta hai. June 2024 mein Kshitij Jaggi aur Kumar Shivang ne RISA Labs ko found kiya tha, jiska aim modern cancer treatment mein inherent critical mathematical challenges ko solve karna hai. RISA Labs ne early-adopting U.S. oncology practices mein significant operational improvements report kiye hain. Startup ka dawa hai ki uska AI lagbhag 80% administrative staff time bachata hai, claim denials ko 40% tak kam karta hai, aur 97.8% first-pass approval rate achieve karta hai. Yeh metrics dikhate hain ki kaise AI ek high-stakes medical field mein efficiency aur cost savings drive kar sakta hai. Yeh investment healthcare sector mein badhti investor interest ke beech aayi hai, khaas kar AI integration mein. Yeh technology manual methods ke comparison mein medical diagnostics mein greater accuracy aur treatment aur diagnosis ke liye faster timeline provide karti hai. Yeh funding round RISA Labs ko 2026 mein oncology mein deeper expansion ke liye position karta hai, partnerships par focus karte hue poore cancer care spectrum ko cover karne ke liye.
RISA Labs ko US Cancer AI Expansion ke liye $11M Mile
HEALTHCAREBIOTECH
Overview
Healthcare AI company RISA Labs ne Cencora Ventures aur Optum Ventures ke co-lead karne par $11.1 million ki Series A funding raise ki hai. Yeh paisa U.S. cancer clinics aur health systems mein AI-powered oncology workflow system, BOSS, ke distribution ko badhane mein madad karega. RISA ka kehna hai ki uska AI administrative time kam karta hai aur approval rates improve karta hai, cancer care mein critical pain points ko address karta hai.
Disclaimer:This content
is for educational and informational purposes only and does not constitute investment, financial, or
trading advice, nor a recommendation to buy or sell any securities. Readers should consult a
SEBI-registered advisor before making investment decisions, as markets involve risk and past performance
does not guarantee future results. The publisher and authors accept no liability for any losses. Some
content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views
expressed do not reflect the publication’s editorial stance.